Eason Zhou

Director in Department of Medicinal Chemistry, 5 PCCs, 1 clinical candidate, 15 patents, 9 papers.

1. Lead optimization of novel irreversible kinase inhibitors to overcome resistance to kinase drugs in cancer: leading a team to successfully get the desired lead compounds in due time. 2. Selective small molecule channel blockers: carrying out the SAR study and managing a FTE team in CRO company.  2013 Excellent employee at Shanghai Haiyan  2014 Excellent employee at Yangtze River Pharmaceutical Group  Eight patents filed in 2014 and 2015

1. Lead-to-candidate study of kinase inhibitors for the treatment of rheumatoid arthritis. >800 target compounds were made in three years. A great milestone in drug R&D was achieved by our team with nomination of several preclinical candidate drugs. 2. Semi-synthetic study on complicated natural product on milligram scale: preparation and application of silyl enol ether, synthesis of alpha-fluoro carbonyl compounds, dehydrogenation of carbonyl compounds to the corresponding alpha,belta-unsaturated compounds, preparation of deuterium-labeled compounds.  Award of Excellence, ChemPartner, Awarded by Genentech (Shanghai, 2012);  Award of Excellence, ChemPartner, Awarded by Genentech (Shanghai, 2011);  Special bonus for my team（$2000, Awarded by Genentech, 2011）；  Award of Excellence, ChemPartner, Awarded by Genentech (Shanghai, 2010).